Transaction DateRecipientSharesTypePriceValue
14th October 2020Bryan Giraudo3,000Open or private purchase$10.01$30,036.00
11th August 2020Chaitan Phd Khosla2,499Open or private sale$17.19$42,952.06
11th August 2020Chaitan Phd Khosla2,499Exercise of derivative$1.89$4,723.11
23rd June 2020Bryan Giraudo2,000Open or private purchase$12.96$25,922.40
29th April 2020Dinesh V Ph D Patel2,000Bona fide gift$0.00
20th March 2020Dinesh V Ph D Patel10,000Exercise of derivative$1.89$18,900.00
12th March 2020Dinesh V Ph D Patel18,344Exercise of derivative$1.16$21,279.04
12th March 2020Harold E Selick12,000Open or private purchase$6.70$80,400.00
14th February 2020Bryan Giraudo46,500Grant/award etc.$0.00
3rd December 2019Dinesh V Ph D Patel10,000Open or private purchase$5.55$55,500.00
Protagonist Therapeutics
Protagonist Therapeutics logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 8/10.


Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The firm's initial lead product candidates are being developed for moderate-to-severe ulcerative colitis and Crohn's disease.


Ticker: PTGX
Sector: Healthcare
Industry: Biotechnology
SEC Central Index Key (CIK): 1377121
Employees: 64
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Fundamentals
Cash at Carrying Value: $146 M (0%)
Marketable Securities, Current: $62 M (0%)
Assets, Current: $217 M (49%)
Property, Plant and Equipment, Net: $2 M (-7%)
Assets: $225 M (45%)
Accounts Payable, Current: $3 M (2%)
Accrued Liabilities, Current: $13 M (4%)
Liabilities, Current: $35 M (0%)
Liabilities: $57 M (-23%)
Common Stock, Shares, Issued: $37 M (35%)
Additional Paid in Capital, Common Stock: $425 M (42%)
Retained Earnings (Accumulated Deficit): $257 M (0%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $208 Th (-5%)
Stockholders' Equity (Parent): $167 M (0%)
Liabilities and Equity: $225 M (45%)
Research and Development: $20 M (-48%)
General and Administrative Expenses: $4 M (-52%)
Operating Income/Loss: $18 M (-51%)
Provision for income taxes: $1 M (2%)